Novavax (NVAX)
(Delayed Data from NSDQ)
$11.99 USD
+0.03 (0.25%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $11.96 -0.03 (-0.25%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Balance Sheet
Fiscal Year End for Novavax, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 579 | 1,347 | 1,527 | 805 | 82 |
Receivables | 297 | 82 | 455 | 262 | 8 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 42 | 37 | 0 | 0 | 0 |
Other Current Assets | 226 | 237 | 174 | 181 | 8 |
Total Current Assets | 1,144 | 1,703 | 2,155 | 1,248 | 97 |
Net Property & Equipment | 306 | 294 | 229 | 180 | 11 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 127 | 126 | 136 | 141 | 57 |
Deposits & Other Assets | 35 | 28 | 57 | 13 | 8 |
Total Assets | 1,797 | 2,259 | 2,577 | 1,582 | 173 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 325 | 0 | 0 | 0 |
Accounts Payable | 133 | 217 | 127 | 54 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 5 | 27 | 131 | 106 | 0 |
Accrued Expenses | 395 | 591 | 674 | 142 | 20 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1,103 | 1,300 | 1,459 | 277 | 3 |
Total Current Liabilities | 1,635 | 2,460 | 2,390 | 580 | 26 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 622 | 179 | 173 | 0 | 3 |
Convertible Debt | 168 | 166 | 323 | 322 | 321 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 56 | 31 | 0 | 40 | 0 |
Other Non-Current Liabilities | 33 | 56 | 42 | 13 | 10 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2,514 | 2,893 | 2,928 | 955 | 359 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 0 |
Capital Surplus | 4,192 | 3,738 | 3,352 | 2,535 | 1,261 |
Retained Earnings | -4,821 | -4,276 | -3,618 | -1,874 | -1,432 |
Other Equity | 3 | -6 | -1 | 7 | -13 |
Treasury Stock | 92 | 91 | 85 | 42 | 3 |
Total Shareholder's Equity | -717 | -634 | -352 | 627 | -186 |
Total Liabilities & Shareholder's Equity | 1,797 | 2,259 | 2,577 | 1,582 | 173 |
Total Common Equity | -717 | -634 | -352 | 627 | -186 |
Shares Outstanding | 118.70 | 78.50 | 75.60 | 63.60 | 32.30 |
Book Value Per Share | -6.04 | -8.08 | -4.65 | 9.86 | -5.76 |
Fiscal Year End for Novavax, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1,060 | 491 | 579 | 662 | 516 |
Receivables | 32 | 21 | 297 | 124 | 395 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 9 | 16 | 42 | 70 | 23 |
Other Current Assets | 102 | 199 | 226 | 152 | 193 |
Total Current Assets | 1,203 | 727 | 1,144 | 1,007 | 1,128 |
Net Property & Equipment | 289 | 291 | 306 | 301 | 300 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 123 | 123 | 127 | 124 | 128 |
Deposits & Other Assets | 34 | 31 | 35 | 35 | 33 |
Total Assets | 1,819 | 1,354 | 1,797 | 1,657 | 1,685 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 80 | 58 | 133 | 102 | 87 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 9 | 6 | 5 | 1 | 1 |
Accrued Expenses | 159 | 257 | 395 | 311 | 458 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 909 | 483 | 1,103 | 1,054 | 1,050 |
Total Current Liabilities | 1,158 | 804 | 1,635 | 1,469 | 1,596 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 533 | 841 | 622 | 609 | 607 |
Convertible Debt | 169 | 168 | 168 | 168 | 167 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 55 | 55 | 56 | 53 | 31 |
Other Non-Current Liabilities | 335 | 33 | 37 | 38 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2,250 | 2,221 | 2,514 | 2,336 | 2,440 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 2 | 1 | 1 | 1 | 1 |
Capital Surplus | 4,478 | 4,205 | 4,192 | 4,067 | 3,856 |
Retained Earnings | -4,806 | -4,969 | -4,821 | -4,643 | -4,512 |
Other Equity | -11 | -11 | 3 | -12 | -8 |
Treasury Stock | 94 | 94 | 92 | 92 | 91 |
Total Shareholder's Equity | -432 | -867 | -717 | -678 | -755 |
Total Liabilities & Shareholder's Equity | 1,819 | 1,354 | 1,797 | 1,657 | 1,685 |
Total Common Equity | -432 | -867 | -717 | -678 | -755 |
Shares Outstanding | 140.40 | 140.40 | 118.70 | 118.70 | 86.30 |
Book Value Per Share | -3.07 | -6.18 | -6.04 | -5.71 | -8.74 |